United States

Analyst Research Report Snapshot


Alnylam Pharmaceuticals, Inc. (ALNY) - Financial and Strategic SWOT Analysis Review






04 Apr 2013





Companies referenced:


Available for Immediate Download

Alnylam Pharmaceuticals, Inc. (ALNY) - Financial and Strategic SWOT Analysis Review Summary Alnylam Pharmaceuticals, Inc., (Alnylam) is a biopharmaceutical company focusing on the discovery, development and commercialization of novel therapeutics based on Ribo Nucleic Acid interference (RNAi). The company is primarily involved in its Alnylam 5x15 program for developing RNAi based therapeutics targeted against genetically defined diseases. Alnylam Pharmaceuticals, Inc. Key Recent Developments: Feb 07, 2013: Alnylam Pharma Reports Revenue Of $8.5m In Q4 2012 Jan 06, 2013: Alnylam Pharma Provides Key 2013 – 2014 Goals For RNAi Therapeutics Pipeline Nov 26, 2012: Alnylam Pharma Receives Notice Of Allowance From USPTO For New Patents From Tuschl II Patent Estate Broadly Covering RNAi Therapeutics Nov 12, 2012: Tekmira Pharma And Alnylam Pharma Restructure Relationship And Settle All Litigation Nov 05, 2012: Alnylam Pharma Reports Revenue Of $16.8m In Q3 2012 This comprehensive SWOT profile of Alnylam Pharmaceuticals, Inc. provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description - A detailed description of the company's operations and business divisions. - Corporate strategy - Analyst's summarization of the company's business strategy. - SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities - A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company's core strengths and weaknesses and areas ...

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.